Tiêu đề 3.2 Inmunoterapia: monoterapia y combinaciones - Dra. Eva Muñoz.pdf ✅

ENFERMEDAD MESTASTÁSICA I: Inmunoterapia: monoterapia y combinaciones (Ipi-Nivo, Nivo-Rela, ...) Dra. Eva Muñoz Couselo, MD, PhD Oncología médica Hospital Vall d’Hebrón, VHIO, Barcelona
Disclosures Consultant or Advisory Role • Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, Pierre Fabre, Roche, Sanofi, Regeneron Research Funding • MSD, Sanofi, BMS Speaking • Amgen, Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, Pierre Fabre, Regeneron Clinical trial participation (principal investigator) • Amgen, Bristol Myers Squibb, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Pierre Fabre, Roche, Sanofi, Iovance, Regeneron
MELANOMA NEOADYUVANCIA Anti-PD-1 BRAFi + MEKi Ensayo clínico Anti-PD-1 Estado III/IV (clínico) ADYUVANCIA ADYUVANCIA mutación Estadio III/IV BRAF Estadio IIB/IIC Estadio III irresecable/IV TRATAMIENTO SISTÉMICO mutación BRAF Anti-PD-1 BRAFi + MEKi Anti-PD-1 + Anti-CTLA4 Anti-PD-1 + Anti-LAG3 1. Robert C et al. N Engl J Med. 2011;364:2517-2526. 2. Wolchok J et al. Presented at ASCO 2011; abstract LBA5. 3. Maio M et al. J Clin Oncol. 2015;33:1191-1196. 4. Robert C et al. N Engl J Med. 2015;372:320-323. 5. Atkinson V et al. Presented at SMR 2015. 6. Larkin J et al. N Engl J Med. 2015;373:23-34. 7. Larkin J et al. Presented at AACR 2017; abstract CT075. 8. Wolchok et al. N Engl J Med. 2017;377:1345-1356. 9. Hodi FS et al. Presented at ESMO 2018; abstract LBA44. 10. Robert C et al. N Engl J Med. 2015;372:2521-2532. 11. Schachter J et al. Lancet. 2017;390:1853-1862. 12. Robert C et al. ASCO 2017; abstract 9504. 13. Long GV et al. Presented at ASCO 2018; abstract 9503. 14. Hodi FS et al. Presented at AACR 2016; abstract CT00. 15. Hamid O et al. Presented at ASCO 2018; abstract 9516. 16. Dummer R et al SMR 2016. 17. Dummer R. et al Lancet Oncol 2018. 18. Dummer R. et al ASCO 2018. 19. Long G.V. et al. NEJM 2014. 20. Long G.V. et al Lancet 2015. 21. Long G.V. Ann Oncol 2017. 22.. Robert C. et al NEJM 2014,. 23. Robert C. et al ESMO 2016. 24.Larkin J. et al NEJM 2014. 25. Ascierto P.A. et al Lancet Oncol 2016; 26. Tawbi et al. NEJM 2022: 27. Mc Arthur AACR 2020; 1. Zimmer et al. lancet 2020; 2. Dummer et al. NEJMM 2020; 3. Eggermont et al. NEJM 2018; 4. Eggermont et al. ASCO 2020; 5. Weber et al. NEJM 2017; 6. Ascierto et al. Lancet 2020; 7. Weber et al. ESMO 2020; 8. Grossman et al. Cancer discovery 2021; 9. Menzies et al. Nature medicina 2021, 8. Rutkowski wt al. Lancet 2022 Anti-PD-1 Anti-PD-1 + Anti-CTLA4
Approved Agents for Stage IV Melanoma Fármacos aprobados para estadio IV en melanoma